These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9577229)

  • 1. Conformational behavior of the HAV-VP3(110-121) peptidic sequence and synthetic analogs in membrane environments studied by CD and computational methods.
    Pérez JA; Cantó J; Reig F; Pérez JJ; Haro I
    Biopolymers; 1998 Jun; 45(7):479-92. PubMed ID: 9577229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chain length of HAV-VP3 synthetic peptides on its interaction with biomembrane models.
    Sospedra P; Muñoz M; García M; Alsina MA; Mestres C; Haro I
    Biopolymers; 2000 Dec; 54(7):477-88. PubMed ID: 10984400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction study of peptide from VP3 capsid protein of hepatitis A virus through monolayers and fluorescence spectroscopy.
    Sospedra P; Prat J; Haro I; Mestres C; Busquets MA
    Luminescence; 2001; 16(2):103-7. PubMed ID: 11312535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phospholipid-model membrane interactions with branched polypeptide conjugates of a hepatitis A virus peptide epitope.
    Nagy IB; Alsina MA; Haro I; Reig F; Hudecz F
    Bioconjug Chem; 2000; 11(1):30-8. PubMed ID: 10639082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane fusion by an RGD-containing sequence from the core protein VP3 of hepatitis A virus and the RGA-analogue: implications for viral infection.
    Chávez A; Pujol M; Haro I; Alsina MA; Cajal Y
    Biopolymers; 2001 Jan; 58(1):63-77. PubMed ID: 11072230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, lipophilic derivatization and interaction with liposomes of HAV-VP3 (102-121) sequence by using spectroscopic techniques.
    Garcia M; Pujol M; Reig F; Alsina MA; Haro I
    Analyst; 1996 Nov; 121(11):1583-8. PubMed ID: 8952449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of synthetic peptides for hepatitis A diagnosis using biosensor technology.
    Gómara MJ; Ercilla G; Alsina MA; Haro I
    J Immunol Methods; 2000 Dec; 246(1-2):13-24. PubMed ID: 11121543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in secondary structure of HAV-synthetic peptides induced by the sequential order of T- and B-cell epitopes.
    Gómara MJ; Girona V; Ercilla G; Reig F; Alsina MA; Haro I
    Biopolymers; 2001 Feb; 58(2):117-28. PubMed ID: 11093111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid phase synthesis and immunogenicity of a VP3 peptide from hepatitis A virus.
    Pérez JA; González-Dankaart JF; Reig F; Pintó RM; Bosch A; Haro I
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):93-100. PubMed ID: 9346860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational preferences of a peptide corresponding to the major antigenic determinant of foot-and-mouth disease virus: implications for peptide-vaccine approaches.
    de Prat-Gay G
    Arch Biochem Biophys; 1997 May; 341(2):360-9. PubMed ID: 9169027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence study on the interaction of a multiple antigenic peptide from hepatitis A virus with lipid vesicles.
    Ortiz A; Cajal Y; Haro I; Reig F; Alsina MA
    Biopolymers; 2000 May; 53(6):455-66. PubMed ID: 10775061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the immunogenicity of a synthetic peptide bearing a VP3 epitope of hepatitis A virus.
    Pintó RM; González-Dankaart JF; Sánchez G; Guix S; Gómara MJ; García M; Haro I; Bosch A
    FEBS Lett; 1998 Oct; 438(1-2):106-10. PubMed ID: 9821968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes as vehicles for the presentation of a synthetic peptide containing an epitope of hepatitis A virus.
    García M; Alsina MA; Reig F; Haro I
    Vaccine; 1999 Sep; 18(3-4):276-83. PubMed ID: 10506652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of a sequential B-epitope in the VP2 protein of hepatitis A virus.
    Kulik LN; Ivanov VS; Tchikin LD; Ostrovsky AG; Ivanov VT
    FEBS Lett; 1995 Jun; 367(1):85-8. PubMed ID: 7541374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational changes of polyomavirus major capsid protein VP1 in sodium dodecyl sulfate solution.
    Yang YW; Teng CC
    J Pept Res; 1999 Jan; 53(1):75-81. PubMed ID: 10195444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain of local structure in an amphipathic peptide does not require a specific tertiary framework.
    Roman EA; Rosi P; González Lebrero MC; Wuilloud R; González Flecha FL; Delfino JM; Santos J
    Proteins; 2010 Oct; 78(13):2757-68. PubMed ID: 20607854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The covalent coupling of HAV-VP3 (110-121) synthetic peptide to liposomes: physicochemical studies.
    Muñoz M; Sospedra P; Gómara MJ; Mestres C; Haro I
    Int J Pharm; 2004 Jan; 269(1):177-84. PubMed ID: 14698589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of membrane mimicking environment on the conformation of a pore-forming (xSxG)6 peptide.
    Thundimadathil J; Roeske RW; Guo L
    Biopolymers; 2006; 84(3):317-28. PubMed ID: 16463358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural variations in nisin associated with different membrane mimicking and pH environments.
    Dykes GA; Hancock RE; Hastings JW
    Biochem Biophys Res Commun; 1998 Jun; 247(3):723-7. PubMed ID: 9647761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-hepatitis A virus antibody response elicited in mice by different forms of a synthetic VP1 peptide.
    Haro I; Pinto RM; Gonzalez-Dankaart JF; Perez JA; Reig F; Bosch A
    Microbiol Immunol; 1995; 39(7):485-90. PubMed ID: 8569533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.